Company Share Option Plan (CSOP)
CSOP is a DISCRETIONARY tax-advantaged share option scheme available to any UK company of any size, in any trade. **Individual cap £60,000, DOUBLED from £30,000 from 6 April 2023** (Finance (No. 2) Act 2023). Company selects which employees receive options + grants them the right to buy shares at TODAY'S MARKET PRICE at a future date (3-10 years after grant). **Tax treatment**: NO income tax + NO NIC at grant or exercise IF (a) exercise is at least 3 YEARS after grant; (b) options exercised at or above market value at grant; (c) qualifying conditions met. Only CGT on eventual disposal. CSOP is the natural successor scheme when a company outgrows EMI (size, headcount, excluded trade). **Key April 2023 reforms**: individual cap doubled to £60,000 + 'WORTH HAVING' SHARE CLASS CONDITION REMOVED (allowing CSOP over growth shares, hurdle shares, non-standard share classes). NO 5% BADR exemption (unlike EMI), standard BADR mechanics apply, typically excluding most CSOP participants from BADR.
Last reviewed:
Guidance, not advice. We explain the rules, we don't assess your situation. Always seek financial or tax advice from your accountant, or contact HMRC. Read our editorial scope →
What this relief is, in plain English
CSOP is the discretionary tax-advantaged share option scheme for UK companies that don't fit EMI's start-up profile. April 2023 reforms doubled the individual cap to £60,000 + removed the 'worth having' share class restriction, making CSOP materially more useful for mid-sized + PE-backed companies. Mechanics: company grants option at market value at grant; employee exercises 3-10 years later; no income tax / NIC if exercised at least 3 years after grant + at market value; only CGT on disposal. Key differences vs EMI: (1) no company size restrictions (any size); (2) no excluded trades (any trade); (3) lower individual cap £60k vs £250k; (4) no BADR 5%-relaxation (standard BADR mechanics, typically inaccessible to typical employees); (5) discretionary participation (vs all-employee for SAYE/SIP). Used by: AIM + Main Market listed companies (large + listed often use CSOP as part of remuneration package); PE-backed scale-ups where the share class structure makes EMI unworkable; companies in excluded trades; mid-sized companies that have grown past EMI thresholds. Many companies operate EMI + CSOP in combination for different employee tiers.
How it works
Grant at market value (AMV), £60k individual cap
Company grants option to selected employee at exercise price = Actual Market Value (AMV) at grant. Maximum value of all subsisting CSOP options per employee: £60,000 (doubled from £30,000 April 2023). Measured by AMV at each grant date. SAV pre-approval recommended (90-day validity). NO income tax + NO NIC at grant.
3-year minimum hold + 10-year maximum exercise window
Option must be exercised AT LEAST 3 YEARS after grant + WITHIN 10 YEARS of grant. Exercise within 3 years (outside good-leaver scenarios) → full income tax + NIC on gain. Exercise at year 3-10 + at or above market value at grant → NO income tax + NO NIC on exercise. Only CGT on subsequent disposal.
April 2023 reforms, £60k cap + worth-having removal
Finance (No. 2) Act 2023 doubled cap from £30k to £60k effective 6 April 2023 + removed 'worth having' share class condition. CSOP now available over growth shares, hurdle shares, restricted shares, non-standard ordinary share classes. Materially more useful for PE-backed + mid-sized companies post-April 2023.
Disposal mechanics, standard CGT, no BADR relaxation
On disposal of CSOP shares: gain at standard CGT rates 18% basic / 24% higher. NO 5% BADR relaxation (unlike EMI). Most CSOP participants don't reach 5% shareholding → standard CGT rates apply. Material difference from EMI on the same gain (EMI BADR 14%/18% vs CSOP CGT 24%).
Who qualifies
- UK company (any size, any trade)
- Employee or full-time director (part-time directors don't qualify, unlike EMI)
- Individual cap £60,000 of subsisting CSOP options at AMV at grant
- Options over ordinary shares, fully paid up, non-redeemable
- From April 2023: 'worth having' condition removed, growth/hurdle/restricted shares OK
- Exercise between 3 + 10 years of grant for income-tax-free treatment
Interactions with other reliefs
EMI
Mutually preferable depending on company eligibility. EMI for start-ups + scale-ups under thresholds; CSOP for larger or excluded-trade companies. Many companies operate both. CSOP options count toward EMI's £250k individual cap if both schemes operated in same company.
BADR
CSOP doesn't carry EMI's 5%-relaxation, standard BADR mechanics apply. Typically inaccessible to most CSOP participants. Material disadvantage vs EMI on disposal at exit.
SAYE + SIP
CSOP discretionary; SAYE + SIP all-employee. Many large companies operate CSOP for senior employees + SAYE / SIP for broader workforce.
Common mistakes + audit triggers
- Exercising within 3 years of grant outside good-leaver scenarios (full income tax + NIC)
- Treating CSOP as having EMI's 5% BADR relaxation (it doesn't)
- Using pre-April-2023 thresholds (£30k cap; 'worth having' condition), both updated
- Granting at below AMV (income tax on the discount on exercise)
Worked example
Adaeze, London - Senior product manager at AIM-listed scale-up, granted CSOP options 2023 (2027-2028)
Adaeze granted £60,000 of CSOP options April 2023 (post-doubling) at £4/share AMV. 15,000 shares total. Vesting + exercises Q3 2027 at £10/share market value. Holds + sells Q3 2028 at £12/share.
Calculation: **Grant (April 2023):** £60,000 of options at £4/share = 15,000 shares. No tax. **Exercise (Q3 2027, 4+ years post-grant):** pays £60,000 to acquire 15,000 shares worth £150,000. No income tax + no NIC (3-year hold met + at AMV). **Disposal (Q3 2028 at £12/share):** 15,000 × £12 = £180,000. Gain: £180,000 - £60,000 = £120,000. **Less AEA £3,000.** Taxable: £117,000. CGT at higher rate 24% = £28,080. **No BADR** (Adaeze holds <5%, typical CSOP position). **Net to Adaeze: £180,000 - £60,000 - £28,080 = £91,920.** Vs equivalent salary at higher rate 42% combined IT+NI: £91,920 net would require ~£158,500 gross salary + ~£23,800 employer NIC = ~£182,300 company cost. **CSOP route company cost: ~£28,080 effective (CT relief on the spread); net employer cost approximately zero.** CSOP delivers ~£182,000 of company cost saving on equivalent £91,920 net-to-employee.
Statute reference: ITEPA 2003 Chapter 8 Part 7 + Schedule 4 + Finance (No.2) Act 2023 ITEPA 2003 ss.521-547 + Sch.4; FA(No.2) 2023 (April 2023 reforms). HMRC manual: ETASSUM40000 onwards.
Frequently asked questions
What happens if I miss the Self Assessment deadline?+
Do I need an accountant or can I file Self Assessment myself?+
How do payments on account work?+
When would I use CSOP instead of EMI?+
What was the April 2023 doubling + the 'worth having' condition removal?+
Why don't CSOP shares qualify for BADR with the 5% relaxation EMI has?+
Can CSOP options be granted over restricted or growth shares post-April 2023?+
Last reviewed: